- ►ahajournals.org H Ashrafian, MP Frenneaux, LH Opie - Circulation, 2007 - Am Heart Assoc Although neurohumoral antagonism has successfully reduced heart failure
morbidity and mortality, the residual disability and death rate remains
unacceptably high. Though abnormalities of myocardial metabolism are ... Cited by 64 - Related articles - All 5 versions
PS Leung - The Journal of Physiology, 2007 - Physiological Soc The systemic renin–angiotensin system (RAS) plays an important role in
regulating blood pressure, electrolyte and fluid homeostasis. However, local
RASs also exist in diverse tissues and organs, where they play a multitude ... Cited by 33 - Related articles - BL Direct - All 11 versions
J Shao, N Iwashita, F Ikeda, T Ogihara, T … - Biochemical and biophysical research communications, 2006 - Elsevier Several epidemiological studies suggested that treatment with angiotensin II
type 1 receptor blocker (ARB) provided a risk reduction of developing type 2
diabetes. In this study, we investigated whether and how ARB treatment can ... Cited by 30 - Related articles - All 6 versions
- ►nursing2008.com F Fyhrquist, O Saijonmaa - Journal of Internal Medicine, 2008 - ccmjournal.org New components and functions of the renin-angiotensin system (RAS) are still
being unravelled. The classical RAS as it looked in the middle 1970s consisted
of circulating renin, acting on angiotensinogen to produce angiotensin I, ... Cited by 22 - Related articles - All 7 versions
KY Chu, PS Leung - Antioxidants & Redox Signaling, 2007 - liebertonline.com G IVEN THAT TYPE 2 diabetes mellitus (T2DM) accounts for >90% of cases of
diabetes and its financial drain on healthcare resources, we are in great need
of alternative ap- proaches to its prevention and treatment. Between 60% ... Cited by 22 - Related articles - BL Direct - All 4 versions
Z Huang, L Jansson - Clinical Science, 2007 - clinsci.org Pravastatin, irbesartan and captopril are frequently used in the treatment of
patients with Type 2 diabetes. These drugs also exert beneficial metabolic
effects, causing an improved glucose tolerance in patients, but the precise ... Cited by 16 - Related articles - Cached - BL Direct - All 9 versions
- ►endojournals.org G Chipitsyna, Q Gong, CF Gray, Y Haroon, E … - Endocrinology, 2007 - Endocrine Soc Angiotensin II (AngII), the principal hormone of the renin-angiotensin system,
is actively generated in the pancreas and has been suggested as a key mediator
of inflammation. Monocyte chemoattractant protein-1 (MCP-1) is a chemokine ... Cited by 15 - Related articles - BL Direct - All 4 versions
S Engeli - Contributions to nephrology, 2006 - content.karger.com Abstract Clinical trials of angiotensin-converting enzyme inhibitors and
angiotensin type 1- receptor blockers have demonstrated a significant reduction
in cardiovascular, renal and new-onset diabetes risk. This finding raises ... Cited by 13 - Related articles - BL Direct - All 5 versions
PS Leung - Diabetic medicine, 2007 - pt.wkhealth.com Large clinical trials have shown that inhibition of the renin-angiotensin system
(RAS) can delay and/or prevent the onset of Type 2 diabetes mellitus (T2DM) in
high-risk individuals, such as those with hypertension or chronic heart ... Cited by 11 - Related articles - BL Direct - All 7 versions
P Ernsberger, RJ Koletsky - Current Opinion in Pharmacology, 2007 - Elsevier Accumulating basic and clinical data support the hypothesis that angiotensin
receptor blockers have beneficial effects on glucose and lipid metabolism that
are not shared by other classes of antihypertensive agents. These metabolic ... Cited by 11 - Related articles - All 2 versions
